1-tert-butyl-2-methyl (2S,4EZ)-4-(methoxyimino)pyrrolidine-1,2-dicarboxylate | 461418-07-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1-tert-butyl-2-methyl (2S,4EZ)-4-(methoxyimino)pyrrolidine-1,2-dicarboxylate
• 英文别名: 1-tert-butyl 2-methyl (2S,4EZ)-4-(methoxyimino)-1,2-pyrrolidinedicarboxylate；1-O-tert-butyl 2-O-methyl (2S)-4-methoxyiminopyrrolidine-1,2-dicarboxylate
• CAS: 461418-07-5
• 化学式: C₁₂H₂₀N₂O₅
• 分子量: 272.301
• InChiKey: MEFZTMJLNNDDJG-VIFPVBQESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  77.4
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1-tert-butyl-2-methyl (2S,4EZ)-4-(methoxyimino)pyrrolidine-1,2-dicarboxylate 在 4-二甲氨基吡啶 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 三氟乙酸 作用下， 以 DMF (N,N-dimethyl-formamide) 、 二氯甲烷 、 水 为溶剂， 反应 0.33h， 生成 (4Z/E, 2S)-methyl-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]-4-methoxyiminopyrrolidine-2-carboxylate
  参考文献：
  名称：

  [EN] PYRROLIDINE DERIVATIVES AS OXYTOCIN ANTAGONISTS
  [FR] DERIVES DE PYRROLIDINE UTILISES EN TANT QU'ANTAGONISTES DE L'OXYTOCINE

  摘要：

  本发明涉及公式（I）的新型吡咯烷衍生物，其几何异构体，其光学活性形式如对映体，非对映体，这些的混合物及其外消旋形式，以及其盐，其中R1选自包括或由H和C1-C6-烷基组成的群，用于预防和/或治疗早产、早产或痛经。

  公开号：

  WO2004005249A1
• 作为产物：
  描述：

  N-Boc-4-氧代-脯氨酸 在 三乙胺 作用下， 以 甲醇 、 正己烷 、 氯仿 、 甲苯 为溶剂， 生成 1-tert-butyl-2-methyl (2S,4EZ)-4-(methoxyimino)pyrrolidine-1,2-dicarboxylate
  参考文献：
  名称：

  [EN] PYRROLIDINE DERIVATIVES AS OXYTOCIN ANTAGONISTS
  [FR] DERIVES DE PYRROLIDINE UTILISES EN TANT QU'ANTAGONISTES DE L'OXYTOCINE

  摘要：

  本发明涉及公式（I）的新型吡咯烷衍生物，其几何异构体，其光学活性形式如对映体，非对映体，这些的混合物及其外消旋形式，以及其盐，其中R1选自包括或由H和C1-C6-烷基组成的群，用于预防和/或治疗早产、早产或痛经。

  公开号：

  WO2004005249A1

文献信息

• Pyrrolidine oxadiazole-and thiadiazole derivatives
  申请人：——

  公开号：US20040220238A1

  公开（公告）日：2004-11-04

  The present invention is related to pyrrolidine oxadiazole and thiadiazole derivatives for use as pharmaceutically active compounds, as well as pharmaceutical formulations containing such pyrrolidine oxadiazole derivatives. Said pyrrolidine derivatives are useful in the treatment and/or prevention of preterm labor, premature birth and dysmenorrhea. In particular, the present invention is related to pyrrolidine derivatives displaying a substantial modulatory, notably an antagonist activity of the oxytocin receptor. More preferably, said compounds are useful in the treatment and/or prevention of disease states mediated by oxytocin, including preterm labor, premature birth and dysmenorrhea. The present invention is furthermore related to novel pyrrolidine derivatives as well as to methods of their preparation. (I) B is a oxadiazole or thiadiazole group. 1

  本发明涉及吡咯烷氧二唑和噻二唑衍生物，用作药物活性化合物，以及含有此类吡咯烷氧二唑衍生物的制药配方。所述吡咯烷衍生物在治疗和/或预防早产、早产和痛经方面具有用途。特别地，本发明涉及显示出显著调节活性，特别是催产素受体拮抗剂活性的吡咯烷衍生物。更具体地，这些化合物在治疗和/或预防由催产素介导的疾病状态方面具有用途，包括早产、早产和痛经。本发明还涉及新型吡咯烷衍生物及其制备方法。(I) B是氧代二唑或噻二唑基团。
• Pyrrolidine ester derivatives with oxytocin modulating activity
  申请人：——

  公开号：US20040147511A1

  公开（公告）日：2004-07-29

  The present invention is related to the use of pyrrolidine esters of formula (I) for the treatment and/or prevention of premature labor, premature birth and dysmenorrhea. In particular, the present invention is related to the use of pyrrolidine esters of formula (I) to modulate, notably to antagonise the oxytocin receptor. The present invention is furthermore related to novel pyrrolidine esters. X is selected from the group consisting of CR 6 R 7 , NOR 6 , NNR 6 R 7 ;R is selected from the group comprising or consisting of C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, saturated or unsaturated 3-8-membered cycloalkyl which may contain 1 to 3 heteroatoms selected of N, O, S, aryl, heteroaryl, C 1 -C 6 -alkyl aryl, C 1 -C 6 -alkyl heteroaryl. R 1 is selected from the group comprising or consisting of C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, aryl, heteroaryl, 3-8-membered cycloalkyl, acyl, C 1 -C 6 -alkyl aryl, C 1 -C 6 -alkyl heteroaryl, said cycloalkyl or aryl or heteroaryl groups may be fused with 1-2 further cycloalkyl or aryl or heteroaryl group. 1

  本发明涉及使用式（I）的吡咯烷酯治疗和/或预防早产、早产和痛经。特别是，本发明涉及使用式（I）的吡咯烷酯来调节，尤其是拮抗催产素受体。本发明还涉及新型吡咯烷酯。其中，X选自CR6R7、NOR6、NNR6R7组成的群；R选自C1-C6烷基、C2-C6烯基、C2-C6炔基、饱和或不饱和的含1到3个N、O、S杂原子的3-8环脂肪环烷基、芳基、杂环芳基、C1-C6烷基芳基、C1-C6烷基杂环芳基组成的群；R1选自C1-C6烷基、C2-C6烯基、C2-C6炔基、芳基、杂环芳基、3-8环脂肪环烷基、酰基、C1-C6烷基芳基、C1-C6烷基杂环芳基，所述环烷基或芳基或杂环芳基基团可以与1-2个进一步的环烷基或芳基或杂环芳基基团融合。
• Pyrrolidine oxadiazole-and thiadiazole oxime derivatives being oxytocin receptor antagonists
  申请人：Schwarz Matthias

  公开号：US20060229343A1

  公开（公告）日：2006-10-12

  The present invention is related to pyrrolidine oxadiazole and thiadiazole derivatives for use as pharmaceutically active compounds, as well as pharmaceutical formulations containing such pyrrolidine oxadiazole derivatives. Said pyrrolidine derivatives are useful in the treatment and/or prevention of preterm labor, premature birth and dysmenorrhea. In particular, the present invention is related to pyrrolidine derivatives displaying a substantial modulatory, notably an antagonist activity of the oxytocin receptor. More preferably, said compounds are useful in the treatment and/or prevention of disease states mediated by oxytocin, including preterm labor, premature birth and dysmenorrhea. The present invention is furthermore related to novel pyrrolidine derivatives as well as to methods of their preparation. B is a oxadiazole or thiadiazole group.

  本发明涉及吡咯烷氧噻二唑和噻二唑衍生物，用作药物活性化合物，以及包含此类吡咯烷氧噻二唑衍生物的制药配方。所述吡咯烷衍生物在治疗和/或预防早产、早产和痛经方面具有用途。特别是，本发明涉及显示出 oxytocin 受体的重要调节作用，特别是拮抗剂活性的吡咯烷衍生物。更具体地说，所述化合物在治疗和/或预防由 oxytocin 介导的疾病状态方面具有用途，包括早产、早产和痛经。本发明还涉及新的吡咯烷衍生物以及它们的制备方法。B 是一个氧噻二唑或噻二唑基团。
• Pyrrolidine oxadiazole- and thiadiazole oxime derivatives being oxytocin receptor antagonists
  申请人：Applied Research Systems ARS Holding N.V.

  公开号：US07115639B2

  公开（公告）日：2006-10-03

  The present invention is related to pyrrolidine oxadiazole and thiadiazole derivatives for use as pharmaceutically active compounds, as well as pharmaceutical formulations containing such pyrrolidine oxadiazole derivatives. Said pyrrolidine derivatives are useful in the treatment and/or prevention of preterm labor, premature birth and dysmenorrhea. In particular, the present invention is related to pyrrolidine derivatives displaying a substantial modulatory, notably an antagonist activity of the oxytocin receptor. More preferably, said compounds are useful in the treatment and/or prevention of disease states mediated by oxytocin, including preterm labor, premature birth and dysmenorrhea. The present invention is furthermore related to novel pyrrolidine derivatives as well as to methods of their preparation. (I) B is a oxadiazole or thiadiazole group

  本发明涉及吡咯烷噁唑和噻唑衍生物，用作药物活性化合物，以及含有此类吡咯烷噁唑衍生物的制药配方。所述吡咯烷衍生物在治疗和/或预防早产、早产和痛经方面有用。特别地，本发明涉及显示 oxytocin 受体的显著调节作用，特别是拮抗剂活性的吡咯烷衍生物。更优选地，这些化合物在治疗和/或预防由 oxytocin 介导的疾病状态，包括早产、早产和痛经方面有用。本发明还涉及新型吡咯烷衍生物以及它们的制备方法。(I) B 是噁唑或噻唑基团。
• PHARMACEUTICALLY ACTIVE PYRROLIDINE ESTER DERIVATIVES
  申请人：Schwarz Matthias

  公开号：US20070129381A1

  公开（公告）日：2007-06-07

  The present invention is related to the use of pyrrolidine esters of formula (I) for the treatment and/or prevention of premature labor, premature birth and dysmenorrhea. In particular, the present invention is related to the use of pyrrolidine esters of formula (I) to modulate, notably to antagonise the oxytocin receptor. The present invention is furthermore related to novel pyrrolidine esters. X is selected from the group consisting of CR 6 R 7 , NOR 6 , NNR 6 R 7 ; R is selected from the group comprising or consisting of C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, saturated or unsaturated 3-8-membered cycloalkyl which may contain 1 to 3 heteroatoms selected of N, O, S, aryl, heteroaryl, C 1 -C 6 -alkyl aryl, C 1 -C 6 -alkyl heteroaryl. R 1 is selected from the group comprising or consisting of C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, aryl, heteroaryl, 3-8-membered cycloalkyl, acyl, C 1 -C 6 -alkyl aryl, C 1 -C 6 -alkyl heteroaryl, said cycloalkyl or aryl or heteroaryl groups may be fused with 1-2 further cycloalkyl or aryl or heteroaryl group.

  本发明涉及使用式（I）的吡咯烷酯治疗和/或预防早产、早产和痛经。特别地，本发明涉及使用式（I）的吡咯烷酯来调节，特别是拮抗催产素受体。本发明还涉及新型吡咯烷酯。其中，X选自CR6R7、NOR6、NNR6R7组成的群；R选自C1-C6烷基、C2-C6烯基、C2-C6炔基、饱和或不饱和的3-8环成员的环烷基，可含1-3个选自N、O、S、芳基、杂芳基、C1-C6烷基芳基、C1-C6烷基杂芳基的杂原子；R1选自C1-C6烷基、C2-C6烯基、C2-C6炔基、芳基、杂芳基、3-8环成员的环烷基、酰基、C1-C6烷基芳基、C1-C6烷基杂芳基，所述环烷基或芳基或杂芳基基团可以与1-2个进一步的环烷基或芳基或杂芳基基团融合。